SCHEMBL3079489

SCHEMBL3079489

CC1(C)CC(=O)Nc2c(CO)cccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 4/20 0.44
RARB P10826 1/20 0.34
RARG P13631 1/20 0.34
HDAC3 O15379 4/20 0.33
HDAC4 P56524 4/20 0.33
HDAC1 Q13547 4/20 0.33
HDAC2 Q92769 4/20 0.33
HDAC8 Q9BY41 4/20 0.33
HDAC6 Q9UBN7 4/20 0.33
HDAC9 Q9UKV0 4/20 0.33
ALDH1A1 P00352 1/20 0.33
AHR P35869 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
BUB1 O43683 2/20 0.32
PDK4 Q16654 2/20 0.32
PGR P06401 1/20 0.32
CREBBP Q92793 1/20 0.31
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6221081 0.87 PDK2 (0.58) PDK2RARBRARGALDH1A1AHR
SCHEMBL5764522 0.77 PDE7A (0.46) PDK2RARBRARGALDH1A1AHR
SCHEMBL8488806 0.76 PDK2 (0.37) PDK2PGR
SCHEMBL15519370 0.76 PDE7A (0.46) PDK2RARBRARGHDAC3HDAC4
SCHEMBL17478594 0.76 PDE7A (0.45) PDK2RARBRARGHDAC9ALDH1A1
SCHEMBL6221451 0.76 AHR (0.54) PDK2RARBRARGAHRPDK4
SCHEMBL10587563 0.76 TYMS (0.38) PDK2RARBRARGAHRTSHR
SCHEMBL15135472 0.75 RARB (0.36) PDK2RARBRARGHDAC3HDAC4
SCHEMBL3072597 0.72 ALOX5 (0.44) PDK2ALDH1A1TSHRCREBBPGSK3B
SCHEMBL9382456 0.72 ALDH1A1 (0.44) PDK2HDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 PDK2 321/4885RARB 1623/4885RARG 2237/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 PDK2 321/4885RARB 1623/4885RARG 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.